OpGen Forum: Community User: Leni22

Ein Insolvenz Unternehmen wie Wirecard mit gut aufgestelltes Unternehmen wie OPGN.. Warum filtert BN solche Spam Kommentare nicht?? Kopf schütteln 🙄

Für die anderen im Forum, Urmel ist selbst Gary und... Ein voll Profi 😂😂😂😂

Welcher Id.... vergleicht Wirdecard, Finanzen, mit Opgen, Bios?? Der hat alle tassen nicht mehr im Schrank oder er hat Null Ahnung.. Oder Hauptsache sinnlose spammen?

Am 12.08. werden dieses veröffentlicht...müssen wir noch ne Woche warten. Viel interessanter als die Zahlen wird der Ausblick sein...hoffe da gibt es paar News.

Hi Urmel, das stimmt ( der Vergleich mit Wirecard, irre, aber leider wahr) ....heute gibt's Bekanntgabe der Quartalszahlen von OPGN, mal sehen ob dieses was bewirken können gen Norden ✍️🤔

Mit den richtigen News ändert sich das hoffentlich demnächst ;)

Die Bewertung von Opgen ist wirklich ein Witz, sogar Wirecard ist noch um ein vielfaches höher bewertet 😅😉

Ist aber nicht nur hier gerade so... keine Ahnung was mit den amis los ist

@Grassi

Genervt... Verkaufen 😁

Langsam nervt‘s mich mit der Opgen. Wie geht’s euch mit dem ständigen Abverkauf?

https://www.team-iha.org/news/fda-opens-door-to-rapid-at-home-testing-that-could könnte einen gewissen Schub mit sich bringen....

@Benjo, der schlüsselsatz>>>Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020<<<und daraufhin nur 5 Tage bis Bekanntgabe der Quartalszahlen. Mal sehen wie es dann ankommt...

Preliminary Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020 GAITHERSBURG, Md., July 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN)(“OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the second quarter of 2020 was approximately $1.2 million up from $1.0 million in the second quarter of 2019. The preliminary financial results for the three months ended June 30, 2020 reflect the consummation of our business combination with Curetis GmbH on April 1, 2020. The results for the six months ended June 30, 2020 will be included in the Company’s Quarterly Report on Form 10-Q and earnings release for the second quarter of 2020. Cash as of June 30, 2020 was approximately $12.8 million, an increase from the $11.5 million as of March 31, 2020. The company also announced accomplishment of the following key milestones in the second quarter of 2020 and year to date: OpGen announced a strategic co-promotion partnership with Menarini Silicon Biosystems to market and sell Menarini’s CELLSEARCH system, CELLSEARCH CEC kit and COVID-19 related products to infectious disease healthcare providers and researchers in North America; OpGen’s subsidiary Curetis GmbH secured access to an additional EUR 5 million tranche in non-dilutive debt financing for COVID-19 related research and development. Subject to certain conditions, Curetis can draw down the tranche at its sole discretion during a nine-month period and the tranche will have a five-year maturity and is interest-only until then; Preliminary data was released from an investigator-initiated collaboration with Karolinska Institutet, Stockholm, Sweden, to identify bacterial co-infections in hospitalized patients with COVID-19 pneumonia. OpGen’s Unyvero HPN Panel for Pneumonia identifies life-threatening bacterial co-infections in COVID-19 patients in just five hours, and Unyvero LRT and LRT BAL panels are FDA-cleared in the U.S. for rapid detection of lower respiratory tract infections such as pneumonia. Furthermore, performance of the Unyvero system was highlighted in several posters and abstracts in ASM Microbe 2020 online; OpGen expanded their partnership with the New York State Department of Health and IDC (Infectious Disease Connect), to continue the collaborative program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. In response to the COVID-19 pandemic in New York State, testing under the program was put on hold by the Wadsworth Center and participating hospitals during Q2 with sites expecting to begin running tests again in Q3; OpGen announced results from a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS) have been pre-published in the Journal of Clinical Microbiology. The study was performed by OpGen’s recentl

Guter Anstieg. Werden Heute News erwartet ?

The long list (alle COvid 19 kandidaten die sich 'noch' im rennen befinden) https://biorender.com/covid-vaccine-tracker/details/v-CV16/-35